公开(公告)号：US20230220012A1

公开(公告)日：2023-07-13

申请号：US17998729

申请日：2021-05-13

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Seong Jun KIM ,  Chonsaeng KIM ,  Kyun Do KIM ,  Dae Gyun AHN ,  Young Chan KWON ,  Keunbon KU ,  Hae Soo KIM ,  Hye Jin SHIN ,  Gun Young YOON ,  In Su HWANG ,  Gi Uk JEONG ,  Sun Hee LEE ,  Mi Hwa KIM ,  Su Min LEE ,  Bum Tae KIM

IPC: C07K14/005 ,  A61K39/215 ,  A61P31/14

CPC classification number: C07K14/005 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20022 ,  C12N2770/20034 ,  C07K2319/03

Abstract: Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.